The Mexico animal healthcare market is projected to grow from $2.13 billion in 2025 to $3.34 billion by 2031, at a CAGR of 7.84%. Growth is fueled by rising spending on companion animals, expanding livestock production, and innovations in veterinary diagnostics and therapeutics. Public policies and private investments are enhancing access to veterinary services, while challenges like high costs and limited rural infrastructure remain. Diagnostics are the fastest-growing segment, and poultry healthcare is expanding rapidly due to biosecurity concerns.
The Mexico animal healthcare market size and growth forecast provide context for readers interested in health-related sectors. For readers following the health sector, here is Pluang's market snapshot as of Nov 06, 2026 20:42 WIB: out of 150 priced US health stocks, 51 rose and 94 fell. Notable movers include XRAY at USD 8.68 with a 1-day change of -13.97% and a typical hold time of 74 days, contrasting with TMDX at USD 77.21 gaining 11.93% and a hold time of 26 days with 100% buy order activity, while BKD fell 11.66% to USD 9.55 with a hold time of 22 days.
Kendal Nutricare Limited will be referred to government and state agencies after refusing to participate in a compliance inquiry by the BBB National Programs’ National Advertising Division. The inquiry followed a challenge by Abbott Laboratories rega...
Rainforest Distribution Corp. has implemented Samsara Route Planning and Commercial Navigation across its direct-store-delivery fleet, unifying routing, navigation, telematics, and compliance on one platform integrated with its SAP system. This upgra...
BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell k...
Canary Capital has launched the Canary Staked INJ ETF (INJC) on Nasdaq, providing investors exposure to INJ, the native token of the Injective blockchain. The ETF not only tracks INJ's price but also earns staking rewards from the network's proof-of-...
IMUNON, Inc. presented new data from its Phase 2 OVATION 2 trial showing that IMNN-001, combined with chemotherapy, significantly enhances anti-tumor T-cell immune responses in advanced ovarian cancer patients. This immune activation correlates with ...
